• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

中国酒精性肝病的流行病学特征:系统评价和荟萃分析。

Epidemiological characteristics of alcohol-related liver disease in China: a systematic review and meta-analysis.

机构信息

Department of Fundamental and Community Nursing, School of Nursing, Nanjing Medical University, 101 Longmian Avenue, Nanjing, 211166, Jiangsu, China.

Shanghai Cancer Institute, Shanghai, 200032, China.

出版信息

BMC Public Health. 2023 Jul 1;23(1):1276. doi: 10.1186/s12889-023-15645-4.

DOI:10.1186/s12889-023-15645-4
PMID:37391815
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10314568/
Abstract

BACKGROUND

This meta-analysis aimed to explore the epidemiological characteristics of alcohol-related liver disease (ALD) in China.

METHODS

Studies published between January 2000 and January 2023 were searched from 3 databases in English and 3 databases in Chinese. DerSimonian-Laird's random-effects model was adopted to calculate the pooled prevalence.

RESULTS

A total of 21 studies were included. The pooled prevalence of ALD was 4.8% (95% CI, 3.6%-6.2%) in the general population, 9.3% (95% CI, 4.4%-16.0%) in males, and 2.0% (95% CI, 0.0%-6.7%) in females. The prevalence was the highest in western China (5.0% [95% CI, 3.3%-6.9%]) and the lowest in central China (4.4% [95% CI, 4.0%-4.8%]). The prevalence among people with different drinking histories (less than 5 years, 5 to 10 years, and over 10 years) was 0.9% (95% CI, 0.2%-1.9%), 4.6% (95% CI, 3.0%-6.5%), and 9.9% (95% CI, 6.5%-14.0%), respectively. The prevalence in 1999-2004 was 4.7% (95% CI, 3.0%-6.7%) and then changed from 4.3% (95% CI, 3.5%-5.3%) in 2005-2010 to 6.7% (95% CI, 5.3%-8.3%) in 2011-2016.

CONCLUSIONS

The prevalence of ALD in China has increased in recent decades, with population-related variations. Targeted public health strategies are needed, especially in high-risk groups, such as male with long-term alcohol drinking.

TRIAL REGISTRATION

The registration number on PROSPERO is CRD42021269365.

摘要

背景

本荟萃分析旨在探讨中国酒精性肝病(ALD)的流行病学特征。

方法

检索了 2000 年 1 月至 2023 年 1 月期间发表的英文 3 个数据库和中文 3 个数据库中的研究。采用 DerSimonian-Laird 的随机效应模型计算合并患病率。

结果

共纳入 21 项研究。普通人群中 ALD 的总患病率为 4.8%(95%CI,3.6%-6.2%),男性为 9.3%(95%CI,4.4%-16.0%),女性为 2.0%(95%CI,0.0%-6.7%)。西部地区的患病率最高(5.0%[95%CI,3.3%-6.9%]),中部地区的患病率最低(4.4%[95%CI,4.0%-4.8%])。不同饮酒史(<5 年、5-10 年、>10 年)人群的患病率分别为 0.9%(95%CI,0.2%-1.9%)、4.6%(95%CI,3.0%-6.5%)和 9.9%(95%CI,6.5%-14.0%)。1999-2004 年的患病率为 4.7%(95%CI,3.0%-6.7%),然后从 2005-2010 年的 4.3%(95%CI,3.5%-5.3%)变为 2011-2016 年的 6.7%(95%CI,5.3%-8.3%)。

结论

中国近几十年来 ALD 的患病率呈上升趋势,存在人群相关的变化。需要采取有针对性的公共卫生策略,特别是针对长期饮酒的男性等高危人群。

试验注册

PROSPERO 注册号为 CRD42021269365。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/928e/10314568/731679d747e0/12889_2023_15645_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/928e/10314568/c93083abc30e/12889_2023_15645_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/928e/10314568/fd980c5b1f78/12889_2023_15645_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/928e/10314568/731679d747e0/12889_2023_15645_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/928e/10314568/c93083abc30e/12889_2023_15645_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/928e/10314568/fd980c5b1f78/12889_2023_15645_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/928e/10314568/731679d747e0/12889_2023_15645_Fig3_HTML.jpg

相似文献

1
Epidemiological characteristics of alcohol-related liver disease in China: a systematic review and meta-analysis.中国酒精性肝病的流行病学特征:系统评价和荟萃分析。
BMC Public Health. 2023 Jul 1;23(1):1276. doi: 10.1186/s12889-023-15645-4.
2
Epidemic characteristics of alcohol-related liver disease in Asia from 2000 to 2020: A systematic review and meta-analysis.2000 年至 2020 年亚洲酒精性肝病的流行特征:系统评价和荟萃分析。
Liver Int. 2022 Aug;42(9):1991-1998. doi: 10.1111/liv.15312. Epub 2022 May 27.
3
Epidemiology of alcoholic and nonalcoholic fatty liver disease in China.中国酒精性和非酒精性脂肪性肝病的流行病学。
J Gastroenterol Hepatol. 2013 Aug;28 Suppl 1:11-7. doi: 10.1111/jgh.12036.
4
Risk factors and protective factors for alcohol-related liver disease: A systematic review and meta-analysis.酒精性肝病的风险因素和保护因素:系统评价和荟萃分析。
Alcohol Clin Exp Res. 2022 Dec;46(12):2128-2136. doi: 10.1111/acer.14951. Epub 2022 Oct 18.
5
Global prevalence, incidence, and outcomes of alcohol related liver diseases: a systematic review and meta-analysis.全球酒精相关性肝病的患病率、发病率和结局:系统评价和荟萃分析。
BMC Public Health. 2023 May 11;23(1):859. doi: 10.1186/s12889-023-15749-x.
6
The effect of exposure to long working hours on alcohol consumption, risky drinking and alcohol use disorder: A systematic review and meta-analysis from the WHO/ILO Joint Estimates of the Work-related Burden of Disease and Injury.暴露于长工时对饮酒、危险饮酒和酒精使用障碍的影响:来自世卫组织/国际劳工组织工作相关疾病和伤害负担联合估算的系统评价和荟萃分析。
Environ Int. 2021 Jan;146:106205. doi: 10.1016/j.envint.2020.106205. Epub 2020 Nov 12.
7
Prevalence, risk factors and burden of diabetic retinopathy in China: a systematic review and meta-analysis.中国糖尿病视网膜病变的患病率、危险因素和负担:系统评价和荟萃分析。
J Glob Health. 2018 Jun;8(1):010803. doi: 10.7189/jogh.08.010803.
8
The national and subnational prevalence of cataract and cataract blindness in China: a systematic review and meta-analysis.中国白内障和盲性白内障的全国和省级流行情况:系统评价和荟萃分析。
J Glob Health. 2018 Jun;8(1):010804. doi: 10.7189/jogh.08.010804.
9
Prevalence of abnormal serum liver enzymes in patients with type 2 diabetes mellitus: a cross-sectional study from China.2型糖尿病患者血清肝酶异常的患病率:一项来自中国的横断面研究。
Postgrad Med. 2016 Nov;128(8):770-776. doi: 10.1080/00325481.2016.1242366. Epub 2016 Oct 17.
10
Prevalence of sarcopenia in older Chinese adults: a systematic review and meta-analysis.老年人肌少症的患病率:系统评价和荟萃分析。
BMJ Open. 2021 Aug 19;11(8):e041879. doi: 10.1136/bmjopen-2020-041879.

引用本文的文献

1
Analysis of Risk Factors for Acute First-Ever Ischemic Stroke in the Elderly Population of Eastern Liaoning Province: A Case-Control Study.辽宁省东部老年人群首次急性缺血性卒中危险因素分析:一项病例对照研究
Int J Gen Med. 2025 May 26;18:2715-2725. doi: 10.2147/IJGM.S512339. eCollection 2025.
2
Metabolic dysfunction-associated fatty liver disease related hepatocellular carcinoma in China: An increasing problem: Letter to the edior on "Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis".中国代谢功能障碍相关脂肪性肝病相关肝细胞癌:一个日益严重的问题:致编辑的信,主题为“代谢功能障碍相关脂肪性肝病相关肝细胞癌的全球患病率:系统评价和荟萃分析”
Clin Mol Hepatol. 2024 Oct;30(4):965-969. doi: 10.3350/cmh.2024.0386. Epub 2024 Jun 18.
3

本文引用的文献

1
A cross-sectional study of alcohol consumption and alcoholic liver disease in Beijing: based on 74,998 community residents.一项关于北京地区饮酒与酒精性肝病的横断面研究:基于 74998 名社区居民。
BMC Public Health. 2022 Apr 12;22(1):723. doi: 10.1186/s12889-022-13175-z.
2
Global burden of cancer in 2020 attributable to alcohol consumption: a population-based study.2020 年全球归因于酒精消费的癌症负担:一项基于人群的研究。
Lancet Oncol. 2021 Aug;22(8):1071-1080. doi: 10.1016/S1470-2045(21)00279-5.
3
Alcohol-related harm during the COVID-19 pandemic.
Research progress and application of liver organoids for disease modeling and regenerative therapy.肝类器官在疾病建模和再生治疗中的研究进展与应用。
J Mol Med (Berl). 2024 Jul;102(7):859-874. doi: 10.1007/s00109-024-02455-3. Epub 2024 May 28.
4
Hovenia dulcis: a Chinese medicine that plays an essential role in alcohol-associated liver disease.枳椇子:一种在酒精性肝病中发挥重要作用的中药。
Front Pharmacol. 2024 Apr 8;15:1337633. doi: 10.3389/fphar.2024.1337633. eCollection 2024.
5
Mortality Burden of Liver Cancer in China: An Observational Study From 2008 to 2020.中国肝癌的死亡负担:一项2008年至2020年的观察性研究。
J Clin Transl Hepatol. 2024 Apr 28;12(4):371-380. doi: 10.14218/JCTH.2023.00455. Epub 2024 Mar 19.
2019冠状病毒病疫情期间与酒精相关的危害。
Lancet Gastroenterol Hepatol. 2021 Jul;6(7):511. doi: 10.1016/S2468-1253(21)00185-0.
4
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.PRISMA 2020 声明:系统评价报告的更新指南。
BMJ. 2021 Mar 29;372:n71. doi: 10.1136/bmj.n71.
5
Alcohol-associated liver disease: A review on its pathophysiology, diagnosis and drug therapy.酒精性肝病:关于其病理生理学、诊断及药物治疗的综述
Toxicol Rep. 2021 Feb 19;8:376-385. doi: 10.1016/j.toxrep.2021.02.010. eCollection 2021.
6
Alcohol-attributed disease burden in four Nordic countries between 2000 and 2017: Are the gender gaps narrowing? A comparison using the Global Burden of Disease, Injury and Risk Factor 2017 study.2000 年至 2017 年间四个北欧国家归因于酒精的疾病负担:性别差距是否在缩小?使用 2017 年全球疾病、伤害和风险因素负担研究进行比较。
Drug Alcohol Rev. 2021 Mar;40(3):431-442. doi: 10.1111/dar.13217. Epub 2020 Nov 18.
7
Epidemiology of non-alcoholic and alcoholic fatty liver diseases.非酒精性和酒精性脂肪性肝病的流行病学
Transl Gastroenterol Hepatol. 2020 Apr 5;5:16. doi: 10.21037/tgh.2019.09.08. eCollection 2020.
8
Prevalence of Alcoholic Fatty Liver Disease Among Adults in the United States, 2001-2016.美国成年人酒精性脂肪肝疾病的患病率,2001-2016 年。
JAMA. 2019 May 7;321(17):1723-1725. doi: 10.1001/jama.2019.2276.
9
Growing burden of alcoholic liver disease in China: A review.中国酒精性肝病负担日益加重:综述。
World J Gastroenterol. 2019 Mar 28;25(12):1445-1456. doi: 10.3748/wjg.v25.i12.1445.
10
Global liver disease burdens and research trends: Analysis from a Chinese perspective.全球肝脏疾病负担与研究趋势:中国视角分析。
J Hepatol. 2019 Jul;71(1):212-221. doi: 10.1016/j.jhep.2019.03.004. Epub 2019 Mar 12.